# Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs

Study · id `cardio:ct-nct04271189` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04271189](<https://clinicaltrials.gov/study/NCT04271189>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04271189

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

## Technical summary

Registry record NCT04271189. Randomized; no masking; primary purpose treatment. Start 2020-09-01 (actual); primary completion 2024-08-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 108 participants (enrolled count; ClinicalTrials.gov record NCT04271189, source copy `cardio:ctgov-nct04271189-2025-03-18`, retrieved 2026-10-26)
- Started: 2020-09-01 (actual) (ClinicalTrials.gov record NCT04271189, source copy `cardio:ctgov-nct04271189-2025-03-18`, retrieved 2026-10-26)
- Primary completion: 2024-08-31 (actual) (ClinicalTrials.gov record NCT04271189, source copy `cardio:ctgov-nct04271189-2025-03-18`, retrieved 2026-10-26)
- Completion: 2024-12-31 (actual) (ClinicalTrials.gov record NCT04271189, source copy `cardio:ctgov-nct04271189-2025-03-18`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT04271189, source copy `cardio:ctgov-nct04271189-2025-03-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04271189-2025-03-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs
- Acronym: MIRACLE
- Condition: Newly Diagnosed Type 2 Diabetes
- Intervention (Drug): Metformin-Sitagliptin-Empaglifozin-Pioglitazone
- Intervention (Drug): Standard of care
- Lead sponsor: Azienda Ospedaliero-Universitaria di Parma
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: ae2c4bf9a8ab47d5b79c5d3d2b591b964198cb97a86e3ee0b0257a15b2fe4d2f
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
